433 related articles for article (PubMed ID: 29582675)
1. Feasibility of the Less Is More Approach in Treating Low-Risk Ductal Carcinoma In Situ Diagnosed on Core Needle Biopsy: Ten-Year Review of Ductal Carcinoma In Situ Upgraded to Invasion at Surgery.
Podoll MB; Reisenbichler ES; Roland L; Bruner A; Mizuguchi S; Sanders MAG
Arch Pathol Lab Med; 2018 Sep; 142(9):1120-1126. PubMed ID: 29582675
[TBL] [Abstract][Full Text] [Related]
2. Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?
Pilewskie M; Stempel M; Rosenfeld H; Eaton A; Van Zee KJ; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3487-3493. PubMed ID: 27172775
[TBL] [Abstract][Full Text] [Related]
3. Concordance between vacuum assisted biopsy and postoperative histology: implications for the proposed Low Risk DCIS Trial (LORIS).
Soumian S; Verghese ET; Booth M; Sharma N; Chaudhri S; Bradley S; Umranikar S; Millican-Slater RA; Hanby AM; Francis A
Eur J Surg Oncol; 2013 Dec; 39(12):1337-40. PubMed ID: 24209431
[TBL] [Abstract][Full Text] [Related]
4. Ductal Carcinoma In Situ - Quo Vadis?
Peltecu G
Chirurgia (Bucur); 2021 Dec; 116(5 Suppl):S5-S6. PubMed ID: 34967322
[TBL] [Abstract][Full Text] [Related]
5. Do Eligibility Criteria for Ductal Carcinoma In Situ (DCIS) Active Surveillance Trials Identify Patients at Low Risk for Upgrade to Invasive Carcinoma?
Oseni TO; Smith BL; Lehman CD; Vijapura CA; Pinnamaneni N; Bahl M
Ann Surg Oncol; 2020 Oct; 27(11):4459-4465. PubMed ID: 32418079
[TBL] [Abstract][Full Text] [Related]
6. Surgical Upstaging Rates for Vacuum Assisted Biopsy Proven DCIS: Implications for Active Surveillance Trials.
Grimm LJ; Ryser MD; Partridge AH; Thompson AM; Thomas JS; Wesseling J; Hwang ES
Ann Surg Oncol; 2017 Nov; 24(12):3534-3540. PubMed ID: 28795370
[TBL] [Abstract][Full Text] [Related]
7. Active surveillance of women diagnosed with atypical ductal hyperplasia on core needle biopsy may spare many women potentially unnecessary surgery, but at the risk of undertreatment for a minority: 10-year surgical outcomes of 114 consecutive cases from a single center.
Farshid G; Edwards S; Kollias J; Gill PG
Mod Pathol; 2018 Mar; 31(3):395-405. PubMed ID: 29099502
[TBL] [Abstract][Full Text] [Related]
8. Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy?
Pilewskie M; Olcese C; Patil S; Van Zee KJ
Ann Surg Oncol; 2016 Dec; 23(13):4253-4261. PubMed ID: 27766556
[TBL] [Abstract][Full Text] [Related]
9. Can tumor-associated macrophages in ductal carcinoma in situ on biopsy predict invasive carcinoma on excision?
Hoskoppal D; Reisenbichler ES
Hum Pathol; 2018 Dec; 82():158-162. PubMed ID: 30067949
[TBL] [Abstract][Full Text] [Related]
10. High EZH2 expression in ductal carcinoma in situ diagnosed on breast core needle biopsy is an independent predictive factor for upgrade on surgical excision.
Genco IS; Ozgultekin B; Hosseini H; Hackman K; Ferreira L; Santagada E; Wahl S; Hajiyeva S
Pathol Res Pract; 2020 Dec; 216(12):153283. PubMed ID: 33197837
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study.
Elshof LE; Tryfonidis K; Slaets L; van Leeuwen-Stok AE; Skinner VP; Dif N; Pijnappel RM; Bijker N; Rutgers EJ; Wesseling J
Eur J Cancer; 2015 Aug; 51(12):1497-510. PubMed ID: 26025767
[TBL] [Abstract][Full Text] [Related]
12. Not All Ductal Carcinomas In Situ Are Created IDLE (Indolent Lesions of Epithelial Origin).
Alexander M; Beyda J; Nayak A; Jaffer S
Arch Pathol Lab Med; 2019 Jan; 143(1):99-104. PubMed ID: 29932858
[TBL] [Abstract][Full Text] [Related]
13. Long term clinical follow-up of atypical ductal hyperplasia and lobular carcinoma in situ in breast core needle biopsies.
Renshaw AA; Gould EW
Pathology; 2016 Jan; 48(1):25-9. PubMed ID: 27020205
[TBL] [Abstract][Full Text] [Related]
14. Ductal carcinoma in situ: Is core needle biopsy ever enough?
Caswell-Smith P; Wall M
J Med Imaging Radiat Oncol; 2017 Feb; 61(1):29-33. PubMed ID: 27554420
[TBL] [Abstract][Full Text] [Related]
15. Optimal management of ductal carcinoma in situ of the breast.
Sakorafas GH; Farley DR
Surg Oncol; 2003 Dec; 12(4):221-40. PubMed ID: 14998563
[TBL] [Abstract][Full Text] [Related]
16. Upgrade rate of intraductal papilloma diagnosed on core needle biopsy in a single institution.
Lin LH; Ozerdem U; Cotzia P; Lee J; Chun J; Schnabel F; Darvishian F
Hum Pathol; 2021 Apr; 110():43-49. PubMed ID: 33159966
[TBL] [Abstract][Full Text] [Related]
17. Factors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ.
Takada K; Kashiwagi S; Asano Y; Goto W; Morisaki T; Takahashi K; Fujita H; Takashima T; Tomita S; Hirakawa K; Ohira M
BMC Cancer; 2020 Jun; 20(1):513. PubMed ID: 32493410
[TBL] [Abstract][Full Text] [Related]
18. Lobular neoplasia in breast core needle biopsy specimens is associated with a low risk of ductal carcinoma in situ or invasive carcinoma on subsequent excision.
Renshaw AA; Derhagopian RP; Martinez P; Gould EW
Am J Clin Pathol; 2006 Aug; 126(2):310-3. PubMed ID: 16891208
[TBL] [Abstract][Full Text] [Related]
19. Is the upgrade rate of atypical ductal hyperplasia diagnosed by core needle biopsy of calcifications different for digital and film-screen mammography?
McLaughlin CT; Neal CH; Helvie MA
AJR Am J Roentgenol; 2014 Oct; 203(4):917-22. PubMed ID: 25247961
[TBL] [Abstract][Full Text] [Related]
20. Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ.
Huo L; Sneige N; Hunt KK; Albarracin CT; Lopez A; Resetkova E
Cancer; 2006 Oct; 107(8):1760-8. PubMed ID: 16977650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
